| __timestamp | CRISPR Therapeutics AG | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 22732000 |
| Thursday, January 1, 2015 | 12573000 | 29245000 |
| Friday, January 1, 2016 | 42238000 | 33206000 |
| Sunday, January 1, 2017 | 69800000 | 31152000 |
| Monday, January 1, 2018 | 113773000 | 10136000 |
| Tuesday, January 1, 2019 | 179362000 | 45546000 |
| Wednesday, January 1, 2020 | 269407000 | 43367000 |
| Friday, January 1, 2021 | 17953000 | 81413000 |
| Saturday, January 1, 2022 | 110250000 | 139304000 |
| Sunday, January 1, 2023 | 130250000 | 192361000 |
| Monday, January 1, 2024 | -2314000 | 159417000 |
In pursuit of knowledge
In the dynamic world of biotechnology, understanding the financial health of companies is crucial. This analysis delves into the cost of revenue trends for Halozyme Therapeutics, Inc. and CRISPR Therapeutics AG from 2014 to 2023. Over this period, CRISPR Therapeutics AG saw a staggering increase in its cost of revenue, peaking in 2020 with a 1,680% rise from its 2014 figures. Meanwhile, Halozyme Therapeutics, Inc. experienced a more modest growth, with a 747% increase by 2023. Notably, 2021 marked a pivotal year for Halozyme, with a 88% surge in costs, reflecting strategic investments. These trends highlight the contrasting financial strategies of these biotech giants, offering insights into their operational priorities and market positioning. As the biotech sector continues to evolve, such financial analyses provide valuable foresight into the industry's future trajectory.
Cost of Revenue Comparison: Novo Nordisk A/S vs CRISPR Therapeutics AG
Cost of Revenue Trends: Amgen Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs CRISPR Therapeutics AG
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Halozyme Therapeutics, Inc. vs CRISPR Therapeutics AG: Strategic Focus on R&D Spending
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
Cost of Revenue Comparison: CRISPR Therapeutics AG vs Evotec SE
Comparing Cost of Revenue Efficiency: CRISPR Therapeutics AG vs Xencor, Inc.